Lincoln Pharma ... the next mid-cap pharma in the making ...?

If we look at last year, the core profit growth YoY has been at 11% while the net profit growth has been at 22% due to the other income.

However the stock p/e excluding the other income is still around 14 (souce screener). Stock still looks cheap to me. But for a rerating they will need to show growth in core business which they have been promising of 15%+